drugset / Trial / NCT04098393
Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to see if a condensed version of the chemotherapy regimen busulfan, melphalan, fludarabine (bu/mel/flu) and the drug antithymocyte globulin (ATG-also referred to as rATG or thymoglobulin) can have the same or fewer number of severe side effects in people with various blood cancers 30 days after they receive an allogeneic hematopoietic cell transplantation.
Timeline
- Start
- 2019-09-18
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | 2.5 mg/kg | — |
| Subject | Busulfan | Small molecule | 0.8 mg/kg | — |
| Subject | Busulfan | Small molecule | 3.2 mg/kg | — |
| Subject | Fludarabine | Small molecule | 25 mg/m2 | — |
| Subject | Melphalan | Small molecule | 70 mg/m2 | — |